Dalpiciclib plus fulvestrant and pyrotinib in HR+/HER2-low advanced breast cancer after progression on CDK4/6 inhibition (DapPLE-HER): a Bayesian optimal phase II study

富维斯特朗 医学 内科学 不利影响 临床终点 肿瘤科 癌症 乳腺癌 胃肠病学 雌激素受体 临床试验
作者
Chunfang Hao,Jing Shi,Yuhua Song,Jie Ma,Hua Yang,Yongsheng Jia,Cuiping Song,Wenjing Meng,Jie Zhang
出处
期刊:International Journal of Surgery [Wolters Kluwer]
卷期号:111 (12): 9210-9218 被引量:2
标识
DOI:10.1097/js9.0000000000003208
摘要

BACKGROUND: The optimal management strategy for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) patients after progression on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) remains undefined. This study aimed to evaluate the efficacy and safety of a combination therapy of dalpiciclib, fulvestrant, and pyrotinib in HR+/HER2-low advanced BC patients with progression on prior CDK4/6i treatment. METHODS: This was an open-label, single-arm, multicenter, Bayesian optimal phase II exploratory study. Eligible patients received dalpiciclib (125 mg/day, 3 weeks on/1 week off), fulvestrant (500 mg intramuscularly every 4 weeks), and pyrotinib (320 mg/day) until disease progression. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety. RESULTS: A total of 30 patients were enrolled in this study. At a median follow-up of 14 months, the median PFS was 4.23 months (95% CI: 2.47-7.90). The ORR was 20.7% (95% CI: 9.8%-38.4%) and the DCR was 51.7% (95% CI: 34.4%-68.6%). The common adverse events (AEs) were diarrhea (83.3%) and decreased white blood cell count (70.0%). Grade 3 AEs were infrequent, and no grade ≥4 AEs were observed. Subgroup analysis revealed that mutation status was significantly associated with PFS ( P = 0.004). CONCLUSION: The combination of dalpiciclib, fulvestrant, and pyrotinib demonstrated modest efficacy with a manageable safety profile in HR+/HER2-low advanced BC patients who had progressed on prior CDK4/6i therapy. This novel regimen demonstrated exploratory efficacy and a favorable safety profile, warranting further validation in future randomized controlled studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
铎铎铎发布了新的文献求助10
刚刚
Mxy发布了新的文献求助10
刚刚
付一鸣发布了新的文献求助10
刚刚
漂亮思菱完成签到,获得积分10
1秒前
Yang发布了新的文献求助10
1秒前
1秒前
peace发布了新的文献求助10
1秒前
even完成签到,获得积分10
1秒前
今后的应助被仇湘采纳,获得10
2秒前
爱博完成签到,获得积分10
2秒前
hzioney完成签到,获得积分10
2秒前
霁月发布了新的文献求助10
2秒前
霁月发布了新的文献求助10
3秒前
霁月发布了新的文献求助10
3秒前
霁月发布了新的文献求助10
3秒前
看海发布了新的文献求助20
3秒前
霁月发布了新的文献求助10
3秒前
霁月发布了新的文献求助10
3秒前
霁月发布了新的文献求助10
3秒前
3秒前
林路路完成签到,获得积分10
3秒前
3秒前
实验室发布了新的文献求助10
3秒前
Dawn完成签到,获得积分10
4秒前
Zzyphyr完成签到,获得积分10
4秒前
4秒前
lailai完成签到,获得积分10
4秒前
安静柚子完成签到,获得积分10
4秒前
诚心冰淇淋完成签到 ,获得积分10
4秒前
朴实钥匙完成签到,获得积分10
5秒前
九毛完成签到,获得积分10
5秒前
blackcat完成签到,获得积分10
5秒前
桐桐的应助被星星采纳,获得10
5秒前
过小完成签到 ,获得积分10
5秒前
5秒前
大个的应助被星星采纳,获得10
5秒前
5秒前
5秒前
今天吃啥菜完成签到,获得积分10
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162